Vertex Pharmaceuticals (VRTX) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Vertex Pharmaceuticals (VRTX)

An SI Board Since August 1996

Posts	SubjectMarks	Bans	Symbol
1169	64	0	VRTX

Emcee: David Lieberman	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
744	Hi quid, I am not really trying to keep up on VTRX so - I may be off on this.	IRWIN JAMES FRANKEL	-	12/9/2005
743	Hi Filo, and I start with this strong disclaimer: you know that I am not the mos	quidditch	-	12/9/2005
742	Hi Quid. Do you or any others have an opinion on the current valuation? This i	FiloF	-	12/9/2005
741	While fast-track designation for 950 wasn't a development out of the blue, i	quidditch	-	12/9/2005
740	FDA Grants Fast Track Designation to Vertex’s Investigational Oral Hepatitis C V	quidditch	-	12/8/2005
739	Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically R	John McCarthy	-	12/7/2005
738	It'll be interesting to see how BAC's holdings in Vertex change at the e	caly	-	11/22/2005
737	Vertex Seen With 'Aggressive' Timing For VX-950 Peter Kang, 11.21.05, 1	tnsaf	-	11/21/2005
736	AASLD Presentations Support the Initiation of a Broad Phase II Program with VX-9	tnsaf	-	11/11/2005
735	late breaking abstracts........ precis.preciscentral.com (thanks, quid!)	scaram(o)uche	-	11/8/2005
734	AASLD Preview of company presenters from GS (good summary of clinical status of	quidditch	-	11/8/2005
733	Coles is gone, if anyone here didn't know. From today's NPS quarterly P	tuck	-	11/4/2005
732	This MDS is new trial, so I guess RA is abandoned. Miljenko	Miljenko Zuanic	-	10/5/2005
731	<<This was a typical case in point of what I was talking about. MMPD, some	Miljenko Zuanic	-	10/5/2005
730	Boger, yup, what you said. And as to 950, it is, but as yet the numbers are so	quidditch	-	10/5/2005
729	>>Any info on SCIO/J&J progress?<< Hard to find the info, but p	tuck	-	10/5/2005
728	This was a typical case in point of what I was talking about. MMPD, something Bo	rkrw	-	10/5/2005
727	totally grand of you to post that link. thanks!	scaram(o)uche	-	10/5/2005
726	[VX-680: "Inhibition of drug-resistant mutants of ABL, KIT, and EGF recepto	tuck	-	10/5/2005
725	It is about time to dump old projects. I am not sure that p38MAP should continue	Miljenko Zuanic	-	10/4/2005
724	Well, everyone clear on that PR? My reaction, fwiw, is a bit troubled, on a num	quidditch	-	10/4/2005
723	>>CAMBRIDGE, Mass., Oct. 4 /PRNewswire-FirstCall/ -- Vertex Pharmaceutical	tuck	-	10/4/2005
722	<<Clinical Update Vertex affirmed today that it remains on track to achie	Miljenko Zuanic	-	10/3/2005
721	Per Tom speak, and analyst speak, she would be right on time, on budget :)--time	quidditch	-	10/3/2005
720	Malloy would be a little late. It has doubled since the UPerform rating back in	LJM	-	10/3/2005

Go to reply# or date (mm/dd/yy):